Combination therapy for glaucoma
AssigneeAllergan, Inc.
InventorsSCOTT M. WHITCUP, ROBERT M. BURK, DAVID W. OLD, YARIV DONDE, WHA-BIN IM, MARK A. HOLOBOSKI
Life of this patent
Estimating the term…
Loading patent…
AssigneeAllergan, Inc.
InventorsSCOTT M. WHITCUP, ROBERT M. BURK, DAVID W. OLD, YARIV DONDE, WHA-BIN IM, MARK A. HOLOBOSKI
Estimating the term…
Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, α2-selective adrenergic agonists, Carbonic Anhydrase Inhibitors, Cholinergic Agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, Glutamate Antagonists, Ca2+ channel blockers, Prostamides, Prostaglandins, Cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed.
A method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from:
or is a salt, isopropyl ester, or a 2-hydroxyethyl ester thereof.
Dependencies are inferred from the claim text.